Replies to post #502 on Aeolus Pharmaceuticals (AOLS)

[MERCURIAL]

https://www.otcmarkets.com/stock/AOLS/news/Aeolus-Announces-Publication-of-Data-Demonstrating-that-Adding-AEOL-10150-to-Standard-Therapy-After-Nerve-Agent-Exposure-Improves-Survival-and-Reduces-Brain-Damage-and-Nerve-Inflammation-in-Rats?id=170261&b=y

"In this and previous publications, we have noted that the addition of AEOL 10150 to the standard of care provides significant protection to susceptible brain areas, reduces associated cognitive impairment and further improves survival outcomes in this rat model. Together with our previous work, this represents a very promising addition to standard care to address the cognitive damage and improve treatment outcomes."